Bajrang Dal leader turned anti-Sangh Parivar crusader Mahendra Kumar dies of cardiac arrest

New Delhi, Mar 12: A PIL was moved in the Delhi High Court on Thursday seeking directions to the Centre to take appropriate steps for stopping religious conversion of socially and economically downtrodden people, particularly of the Scheduled Caste/Scheduled Tribe community.

The plea claims that the government has done nothing to stop religious conversions.

The plea is listed before a bench of Chief Justice D N Patel and Justice C Hari Shankar on Friday.

The petition, by BJP leader and lawyer Ashwini Kumar Upadhyay, alleges that many individuals, NGOs and institutions are converting downtrodden persons by "intimidating, threatening, luring by monetary benefits and by other acts, including miracle healing, black magic and more".

"Many individuals/organizations have started conversions of SC/STs in rural areas and the situation is very alarming. The mass religious conversion of the socially economically downtrodden men, women and children, and, in particular of the scheduled caste and scheduled tribe community, is on the rise in the last 20 years," the petition claims.

It further claims as per the 2011 census, Hindus constitute 79 per cent of the population down from 86 per cent in 2001 and if no action is taken "Hindus will become minority in India".

Upadhyay suggested enacting of a law to prevent conversions by force or deceit and to award jail term for any violation.

"Additionally, the State may empower the National Human Rights Commission to deal with the affairs of religious groups and analyse religious discrimination among them," he suggests.

Apart from seeking steps to prevent religious conversions by force, threats or deceit, the petition also wants directions prohibiting religious gatherings "intended to mislead people by making false and untenable claims" to lure ignorant masses to join a particular faith or religious group.

Bengaluru, Jun 23: Karnataka Medical Education Minister K Sudhakar's wife and daughter have tested positive for COVID-19, a day after his father was confirmed to have been infected with the virus.

"Test results of our family members have come. Unfortunately, my wife and daughter have tested positive for #Covid19 and are undergoing treatment," the minister tweeted on Tuesday.

He said he and his two sons have tested negative.

Sudhakar's father P N Keshava Reddy tested positive for coronavirus on Monday. He was admitted to the hospital with a cough and fever.

Earlier, the domestic help of the minister had tested coronavirus positive and was admitted to a hospital.

In April, Sudhakar was quarantined along with three other ministers for coming in contact with a journalist who was coronavirus positive.

Karnataka reported 249 new COVID-19 cases and five deaths on Monday taking the total number of cases in the state to 9,399 and the death toll to 142.

Test results of our family members have come. Unfortunately, my wife and daughter have tested positive for #Covid19 and are undergoing treatment. My two sons and myself have tested negative. I am grateful to everyone for their best wishes and prayers.

— Dr Sudhakar K (@mla_sudhakar) June 23, 2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.